论文部分内容阅读
目的:分析血塞通注射液和尼莫地平注射液用于治疗脑梗塞患者的药物经济学。方法:选取2015年6—12月期间收治的脑梗塞患者108例作为患者,将其随机分为血塞通组54例与尼莫地平组54例;血塞通组患者均给予血塞通治疗,尼莫地平组患者均给予尼莫地平治疗,分析两组患者治疗后的总有效率及成本-效果。结果:血塞通组患者治疗后的总有效率为88.89%,尼莫地平组患者治疗后的总有效率为90.74%,经组间数据的比较其差异无统计学意义(P>0.05);血塞通组患者治疗的成本-效果比值为25.01优于尼莫地平组患者治疗的成本-效果比值为32.33(P<0.05);~△C/~△E为22.74小于尼莫地平为30.74(P<0.05)。结论:采用血塞通与尼莫地平分别治疗脑梗塞患者,其总有效率及成本-效果均较为理想,但血塞通价格更具优势,成本-效果比值低于尼莫地平组。
OBJECTIVE: To analyze the pharmacology of Xuesaitong injection and nimodipine injection for the treatment of patients with cerebral infarction. Methods: A total of 108 patients with cerebral infarction admitted from June to December in 2015 were selected as patients and randomly divided into Xuesaitong group (n = 54) and nimodipine group (n = 54). Xuesaitong group , Nimodipine group were given nimodipine treatment, analysis of two groups of patients after treatment, the total efficiency and cost-effectiveness. Results: The total effective rate of Xuesaitong group was 88.89%. The total effective rate of Nimodipine group after treatment was 90.74%. There was no significant difference between the two groups (P> 0.05). The cost-effect ratio of Xuesaitong group was 25.01, which was better than that of nimodipine group (32.33, P <0.05). The △ C / ~ △ E was 22.74 less than that of nimodipine 30.74 P <0.05). CONCLUSION: Xuesaitong and Nimodipine are effective in treating cerebral infarction patients, respectively. The total effective rate and cost-effectiveness are all satisfactory, but Xuesaitong price has more advantages and the cost-effectiveness ratio is lower than that of nimodipine group.